Cargando…

Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients

BACKGROUND: Earlier studies have mainly reported the use of antithrombotic drugs, beta-blockers and statins among hospital patient populations or MI patients. This study aimed to describe the use of these drugs among middle-aged Finnish coronary patients and to identify patient groups in risk of bei...

Descripción completa

Detalles Bibliográficos
Autores principales: Manderbacka, Kristiina, Keskimäki, Ilmo, Reunanen, Antti, Klaukka, Timo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2459171/
https://www.ncbi.nlm.nih.gov/pubmed/18590524
http://dx.doi.org/10.1186/1475-9276-7-16
_version_ 1782157407338627072
author Manderbacka, Kristiina
Keskimäki, Ilmo
Reunanen, Antti
Klaukka, Timo
author_facet Manderbacka, Kristiina
Keskimäki, Ilmo
Reunanen, Antti
Klaukka, Timo
author_sort Manderbacka, Kristiina
collection PubMed
description BACKGROUND: Earlier studies have mainly reported the use of antithrombotic drugs, beta-blockers and statins among hospital patient populations or MI patients. This study aimed to describe the use of these drugs among middle-aged Finnish coronary patients and to identify patient groups in risk of being prescribed inadequate medication for secondary prevention of coronary heart disease. METHODS: One-year follow-up survey data from a random sample of a cohort of coronary patients were used along with register data linked to the survey. The response rate was 54% (n = 2650). The main outcome measures were use of antithrombotic drugs, beta-blockers and statins and the data were analysed using logistic regression analysis. RESULTS: Among men and women, respectively, 82% and 81% used beta-blockers, 95% and 89% used antithrombotic drugs, and 62% and 59% used statins. Younger men and men from higher socioeconomic groups were more likely to use statins, even after controlling for disease severity and comorbidity. In women, the age trend was reversed and no socioeconomic differences were found. Drug use increased with increased disease severity, but diabetes had only a slight effect. CONCLUSION: The use of antithrombotic drugs and beta-blockers among Finnish coronary patients seemed to be rather appropriate and, to some extent, prescription practices of preventive medication varied according to patients' risk of coronary events. However, statin use was remarkably low among men with low socio-economic status, and there is need to improve preventive drug treatment among diabetic coronary patients.
format Text
id pubmed-2459171
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24591712008-07-12 Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients Manderbacka, Kristiina Keskimäki, Ilmo Reunanen, Antti Klaukka, Timo Int J Equity Health Research BACKGROUND: Earlier studies have mainly reported the use of antithrombotic drugs, beta-blockers and statins among hospital patient populations or MI patients. This study aimed to describe the use of these drugs among middle-aged Finnish coronary patients and to identify patient groups in risk of being prescribed inadequate medication for secondary prevention of coronary heart disease. METHODS: One-year follow-up survey data from a random sample of a cohort of coronary patients were used along with register data linked to the survey. The response rate was 54% (n = 2650). The main outcome measures were use of antithrombotic drugs, beta-blockers and statins and the data were analysed using logistic regression analysis. RESULTS: Among men and women, respectively, 82% and 81% used beta-blockers, 95% and 89% used antithrombotic drugs, and 62% and 59% used statins. Younger men and men from higher socioeconomic groups were more likely to use statins, even after controlling for disease severity and comorbidity. In women, the age trend was reversed and no socioeconomic differences were found. Drug use increased with increased disease severity, but diabetes had only a slight effect. CONCLUSION: The use of antithrombotic drugs and beta-blockers among Finnish coronary patients seemed to be rather appropriate and, to some extent, prescription practices of preventive medication varied according to patients' risk of coronary events. However, statin use was remarkably low among men with low socio-economic status, and there is need to improve preventive drug treatment among diabetic coronary patients. BioMed Central 2008-06-30 /pmc/articles/PMC2459171/ /pubmed/18590524 http://dx.doi.org/10.1186/1475-9276-7-16 Text en Copyright © 2008 Manderbacka et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Manderbacka, Kristiina
Keskimäki, Ilmo
Reunanen, Antti
Klaukka, Timo
Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
title Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
title_full Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
title_fullStr Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
title_full_unstemmed Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
title_short Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients
title_sort equity in the use of antithrombotic drugs, beta-blockers and statins among finnish coronary patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2459171/
https://www.ncbi.nlm.nih.gov/pubmed/18590524
http://dx.doi.org/10.1186/1475-9276-7-16
work_keys_str_mv AT manderbackakristiina equityintheuseofantithromboticdrugsbetablockersandstatinsamongfinnishcoronarypatients
AT keskimakiilmo equityintheuseofantithromboticdrugsbetablockersandstatinsamongfinnishcoronarypatients
AT reunanenantti equityintheuseofantithromboticdrugsbetablockersandstatinsamongfinnishcoronarypatients
AT klaukkatimo equityintheuseofantithromboticdrugsbetablockersandstatinsamongfinnishcoronarypatients